» Articles » PMID: 19901977

Epidemiological Pathology of Dementia: Attributable-risks at Death in the Medical Research Council Cognitive Function and Ageing Study

Overview
Journal PLoS Med
Specialty General Medicine
Date 2009 Nov 11
PMID 19901977
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dementia drug development aims to modulate pathological processes that cause clinical syndromes. Population data (epidemiological neuropathology) will help to model and predict the potential impact of such therapies on dementia burden in older people. Presently this can only be explored through post mortem findings. We report the attributable risks (ARs) for dementia at death for common age-related degenerative and vascular pathologies, and other factors, in the MRC Cognitive Function and Ageing Study (MRC CFAS).

Methods And Findings: A multicentre, prospective, longitudinal study of older people in the UK was linked to a brain donation programme. Neuropathology of 456 consecutive brain donations assessed degenerative and vascular pathologies. Logistic regression modelling, with bootstrapping and sensitivity analyses, was used to estimate AR at death for dementia for specific pathologies and other factors. The main contributors to AR at death for dementia in MRC CFAS were age (18%), small brain (12%), neocortical neuritic plaques (8%) and neurofibrillary tangles (11%), small vessel disease (12%), multiple vascular pathologies (9%), and hippocampal atrophy (10%). Other significant factors include cerebral amyloid angiopathy (7%) and Lewy bodies (3%).

Conclusions: Such AR estimates cannot be derived from the living population; rather they estimate the relative contribution of specific pathologies to dementia at death. We found that multiple pathologies determine the overall burden of dementia. The impact of therapy targeted to a specific pathology may be profound when the dementia is relatively "pure," but may be less impressive for the majority with mixed disease, and in terms of the population. These data justify a range of strategies, and combination therapies, to combat the degenerative and vascular determinants of cognitive decline and dementia. Please see later in the article for the Editors' Summary.

Citing Articles

Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease.

Walker L, Simpson H, Thomas A, Attems J Acta Neuropathol Commun. 2024; 12(1):28.

PMID: 38360761 PMC: 10870546. DOI: 10.1186/s40478-023-01714-7.


Prevalence of Concomitant Pathologies in Parkinson's Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms.

Walker L, Attems J J Parkinsons Dis. 2023; 14(1):35-52.

PMID: 38143370 PMC: 10836576. DOI: 10.3233/JPD-230154.


Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia.

Hainsworth A, Markus H, Schneider J Hypertension. 2023; 81(1):75-86.

PMID: 38044814 PMC: 10734789. DOI: 10.1161/HYPERTENSIONAHA.123.19943.


Serum Proteomics Identified TAFI as a Potential Molecule Facilitating the Migration of Peripheral Monocytes to Damaged White Matter During Chronic Cerebral Hypoperfusion.

Wang Y, Cheng W, Chen X, Cheng C, Zhang L, Huang W Neurochem Res. 2023; 49(3):597-616.

PMID: 37978153 DOI: 10.1007/s11064-023-04050-3.


Insights into the pathological basis of dementia from population-based neuropathology studies.

Wharton S, Simpson J, Ince P, Richardson C, Merrick R, Matthews F Neuropathol Appl Neurobiol. 2023; 49(4):e12923.

PMID: 37462105 PMC: 10946587. DOI: 10.1111/nan.12923.


References
1.
Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

2.
Sonnen J, Larson E, Crane P, Haneuse S, Li G, Schellenberg G . Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007; 62(4):406-13. DOI: 10.1002/ana.21208. View

3.
. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997; 18(4 Suppl):S1-2. View

4.
Bjertness E, TORVIK A, Ince P, Edwardson J . Validation of Norwegian death certificates on dementia in residents of nursing homes. Epidemiology. 1998; 9(5):584-6. DOI: 10.1097/00001648-199809000-00027. View

5.
Zaccai J, Brayne C, McKeith I, Matthews F, Ince P . Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology. 2008; 70(13):1042-8. DOI: 10.1212/01.wnl.0000306697.48738.b6. View